Integra LifeSciences Holdings Corporation ( IART ) NASDAQ Global Select

Cena: 11.63 ( 0.26% )

Aktualizacja 06-23 21:17
NASDAQ Global Select
Branża: Medical - Devices
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 3 946
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 85%
Ilość akcji: 78 175 800
Debiut giełdowy: 1995-08-16
WWW: https://www.integralife.com
CEO: Mr. Jan De Witte
Adres: 1100 Campus Road
Siedziba: 08540 Princeton
ISIN: US4579852082
Opis firmy:

Integra Lifesciences Holdings Corporation opracowuje, produkuje i sprzedaje implanty chirurgiczne i instrumenty medyczne do stosowania w neurochirurgii, rekonstrukcji kończyn i operacji ogólnej. Działa w dwóch segmentach, Codman Specialty Surgical and Tissue Technologies. Firma oferuje produkty neurochirurgii i neuro krytycznej opieki, w tym sprzęt do ablacji tkanek, produkty naprawcze, urządzenia do zarządzania płynami kręgosłupa mózgowego, sprzęt monitorowania śródczaszkowego oraz sprzęt stabilizacji czaszki; oraz chirurgiczne reflektory i oprzyrządowanie, a także oprogramowanie i wsparcie zarządzania zasobami oraz usługi po rynku. Sprzedaje również około 40 000 wzorów instrumentów oraz produkty chirurgiczne i oświetleniowe szpitalom i centrom chirurgicznym, a także dentystyczne, podiatryczne i weterynaryjne. Ponadto firma zapewnia produkty technologiczne regeneracyjne do leczenia ostrych i przewlekłych ran; oraz chirurgiczne produkty do naprawy przepukliny, naprawa i ochrony nerwów peryferyjnych oraz naprawa ścięgien. Ponadto oferuje produkty do naprawy skóry i ran, tworzywa sztucznego i chirurgicznych, przeszczepów kości oraz produktów naprawczych nerwów i ścięgien. Firma oferuje swoje produkty bezpośrednio za pośrednictwem różnych sił sprzedaży i innych kanałów dystrybucyjnych w szpitalach, zintegrowanych sieci zdrowotnych, organizacji zakupów grupy, klinicystów, centrów chirurgicznych i świadczeniodawców w Stanach Zjednoczonych, Europie, Azji i Pacyfiku i międzynarodowym. Integra Lifesciences Holdings Corporation została zarejestrowana w 1989 roku i ma siedzibę w Princeton, New Jersey.

Wskaźniki finansowe
Kapitalizacja (USD) 903 794 049
Aktywa: 4 065 803 000
Cena: 11.63
Wskaźnik Altman Z-Score: 1.3
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -30.6
Ilość akcji w obrocie: 85%
Średni wolumen: 1 166 508
Ilość akcji 77 712 300
Wskaźniki finansowe
Przychody TTM 1 564 920 000
Zobowiązania: 2 544 216 000
Przedział 52 tyg.: 11.06 - 32.66
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: -0.4
P/E branży: 26.8
Beta: 1.084
Raport okresowy: 2025-07-28
WWW: https://www.integralife.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Jan De Witte President, Chief Executive Officer & Director 888 667 1964
Ms. Lea Daniels Knight Executive Vice President & Chief Financial Officer 673 147 1972
Mr. Michael J. McBreen Executive Vice President & President of Codman Specialty Surgical 611 277 1967
Mr. Eric Ian Schwartz Executive Vice President, Chief Legal Officer & Secretary 549 518 1969
Mr. Robert T. Davis Jr. Executive Vice President & President of Tissue Technologies 529 052 1959
Mr. Jeffrey A. Mosebrook Senior Vice President of Finance & Principal Accounting Officer 493 138 1976
Dr. Stuart M. Essig Ph.D. Executive Chairman 152 500 1962
Laurene Isip Vice President of Global Corporate Communications & Public Relations 0 0
Mr. Stephen Leonard Corporate Vice President of Global Operations & Supply Chain 0 1962
Ms. Ruth L. Fleming Vice President of Global Marketing 0 0
Wiadomości dla Integra LifeSciences Holdings Corporation
Tytuł Treść Źródło Aktualizacja Link
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com 2025-05-16 13:00:00 Czytaj oryginał (ang.)
IART Investors Have Opportunity to Join Integra LifeSciences Holdings Corporation Fraud Investigation with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)--IART Investors Have Opportunity to Join Integra LifeSciences Holdings Corporation Fraud Investigation with the Schall Law Firm. businesswire.com 2025-05-15 22:23:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com 2025-05-14 13:00:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com 2025-05-13 16:10:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com 2025-05-10 12:00:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com 2025-05-09 14:41:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com 2025-05-08 12:00:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com 2025-05-07 12:00:00 Czytaj oryginał (ang.)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com 2025-05-06 22:45:00 Czytaj oryginał (ang.)
Integra Q1 Earnings Miss Estimates, Stock Down, '25 EPS Outlook Cut IART's first-quarter 2025 earnings lag the consensus mark. Q2 revenue projections are bleak. zacks.com 2025-05-06 14:05:43 Czytaj oryginał (ang.)
Integra LifeSciences Holdings Corporation (IART) Q1 2025 Earnings Call Transcript Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Mojdeh Poul - President and Chief Executive Officer Lea Knight - Executive Vice President and Chief Financial Officer Conference Call Participants Young Li - Jefferies Iseult McMahon - BTIG Vik Chopra - Wells Fargo Lilia-Celine Lozada - JPMorgan Ravi Misra - Truist Securities Anthony Occhiogrosso - Citi Jayson Bedford - Raymond James Craig Bijou - Bank of America Securities Operator Good day and thank you for standing by. Welcome to the Integra LifeSciences First Quarter 2025 Financial Results Call. seekingalpha.com 2025-05-05 17:54:21 Czytaj oryginał (ang.)
Compared to Estimates, Integra (IART) Q1 Earnings: A Look at Key Metrics The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-05-05 14:35:47 Czytaj oryginał (ang.)
Integra LifeSciences (IART) Q1 Earnings Miss Estimates Integra LifeSciences (IART) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.55 per share a year ago. zacks.com 2025-05-05 12:40:35 Czytaj oryginał (ang.)
Integra LifeSciences Reports First Quarter 2025 Financial Results PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. globenewswire.com 2025-05-05 10:30:00 Czytaj oryginał (ang.)
Burn Care Market worth $3.35 billion by 2030 with 5.6% CAGR | MarketsandMarkets™ DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Burn Care Market, valued at US$2.46 billion in 2024, is forecasted to grow at a robust CAGR of 5.6%, reaching US$2.55 billion in 2025 and an impressive US$3.35 billion by 2030. This market is experiencing consistent growth due to several key factors. The number of burn injuries is rising due to factors such as industrial accidents, domestic fires, and other hazards. Furthermore, advancements in treatment technologies and increased awareness and education about burn care contribute to this trend. Additionally, supportive government initiatives play a significant role in market development. The demand for effective burn treatments is rising as the global population ages. Older individuals are more susceptible to slow-healing wounds and burn complications, which, in turn, increases the need for advanced burn care products. Moreover, technological advancements in burn treatment—including innovative burn dressings, biologics, and advanced burn wound assessment devices—enhance treatment efficiency and effectiveness. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=247121470 Browse in-depth TOC on "Burn Care Market" 345 - Tables 45 - Figures 302 - Pages By Based on products, the burn care market is categorized into five segments: advanced burn dressings, burn wound therapy devices, biologics, traditional burn care products, and other burn care products. Among these, the biologics segment is expected to register the highest CAGR during the forecast period. This growth is driven by the rising demand for advanced and effective treatment options for deep and complex burns. Biologics provide targeted healing, minimize long-term complications, and promote tissue regeneration, making them particularly suitable for treating severe burns. The increasing acceptance of these products among healthcare professionals and ongoing innovations in regenerative medicine are contributing to the strong and sustained growth of the biologics segment. By Based on burn degree, the burn care market is divided into first-degree burns (minor burns), second-degree burns (partial-thickness burns), and third-degree burns (full-thickness burns). Of these, the second-degree burns segment accounted for the largest market share of the burn care market in 2024. This is largely because partial-thickness burns occur more frequently. These burns tend to destroy the epidermis and dermis; as such, they require the application of advanced burn care products, which drives consistent demand in this segment. By geography, the market for burn care is divided into five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the burn care market in 2024 with the largest market share. This is primarily because countries like the US and Canada have well-developed healthcare facilities, supporting widespread access to advanced burn care products and treatments. The region also experiences a high rate of burn injuries. The availability of key players and constant investment in research & development further consolidate North America's position in the burn care market. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=247121470 The major players operating in this market are Smith+Nephew (UK), Mölnlycke Health Care AB (Sweden), Cardinal Health Inc. (US), Integra LifeSciences Holdings Corporation (US), ConvaTec Group Plc (UK), Coloplast Group (Denmark), Solventum Corporation (US), Essity Aktiebolag (Sweden), PAUL HARTMANN AG (Germany), and Organogenesis Holdings Inc. (US). SMITH+NEPHEW (UK) Smith+Nephew is distinguished by its advanced wound care solutions and robust research and development capabilities, enabling it to provide effective burn care products. Mölnlycke Health Care AB has solidified its market position through strategic partnerships. Cardinal Health Inc. utilizes its extensive distribution network and diverse product line to reach a wide range of healthcare facilities, thereby increasing its share in the burn care market. Integra LifeSciences Holdings Corporation is recognized for its broad range of biologics that offer crucial support for severe burns. ConvaTec Group Plc has strengthened its market presence through global expansion and strategic acquisitions. MOLNLYCKE HEALTH CARE AB (SWEDEN): Mölnlycke Health Care AB also boasts a comprehensive product portfolio in the advanced wound care market. The company's leading position in this sector is largely due to its robust global sales and distribution network, which allows it to effectively market its products in various countries. Mölnlycke primarily utilizes inorganic strategies, such as partnerships, to maintain its market position. For example, in May 2024, the company formed a new partnership with the Phoenix Society, a burn survivor organization in the US. Through this collaboration, Mölnlycke will support the Phoenix Society's initiatives with its extensive range of burn care solutions For more information, Inquire Now! Related Reports: Wound Care Biologics Market Advanced Wound Care Market Point of Care Diagnostics Market Wound Care Market Point of Care Molecular Diagnostics Market Get access to the latest updates on Burn Care Companies and Burn Care Market Size About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg https://www.prnewswire.com 2025-05-02 14:15:00 Czytaj oryginał (ang.)
Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025 PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. globenewswire.com 2025-04-18 20:30:00 Czytaj oryginał (ang.)
Is This the Right Time to Hold Integra Stock in Your Portfolio? IART stays on investors' radar courtesy of its strong prospects in the CSS segment and international growth. zacks.com 2025-03-26 11:35:24 Czytaj oryginał (ang.)
Notice to Long-Term Integra Lifesciences Holdings Corporation (NASDAQ: IART) Shareholders: Grabar Law Investigates Claims on Your Behalf PHILADELPHIA, March 22, 2025 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company. globenewswire.com 2025-03-22 14:10:00 Czytaj oryginał (ang.)
Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET. globenewswire.com 2025-03-13 19:00:00 Czytaj oryginał (ang.)
Integra LifeSciences: Light At The End Of The Tunnel, Or Another Oncoming Train? (Rating Upgrade) Integra LifeSciences had a rough 2024 as the company's quality control remediation efforts had a bigger than expected negative impact on results. Q4 '24 offered some stability with organic revenue growth and improved adjusted gross margins. 2025 guidance looks cautious, and a big cut to Q1 '25 expectations suggests that management may be pulling forward some of the lingering remediation costs. seekingalpha.com 2025-03-06 09:23:30 Czytaj oryginał (ang.)
INTEGRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. (NASDAQ: IART) on behalf of long-term stockholders following a class action complaint that was filed against Integra on September 12, 2023 with a Class Period from March 11, 2019 to May 22, 2023. Our investigation concerns whether the board of directors of Integra have breached their fiduciary duties to the company. globenewswire.com 2025-02-25 23:00:00 Czytaj oryginał (ang.)
Integra LifeSciences Holdings Corporation (IART) Q4 2024 Earnings Call Transcript Integra LifeSciences Holdings Corporation (IART) Q4 2024 Earnings Call Transcript seekingalpha.com 2025-02-25 12:50:53 Czytaj oryginał (ang.)
Integra (IART) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2025-02-25 12:35:40 Czytaj oryginał (ang.)
Integra LifeSciences (IART) Surpasses Q4 Earnings Estimates Integra LifeSciences (IART) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.89 per share a year ago. zacks.com 2025-02-25 10:15:26 Czytaj oryginał (ang.)
Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com 2025-02-25 08:00:00 Czytaj oryginał (ang.)
Jan De Witte joins GHO Capital as Operating Partner Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. globenewswire.com 2025-02-11 06:30:00 Czytaj oryginał (ang.)
Notice To Long-Term Integra Lifesciences Holdings Corporation (NASDAQ: IART) Shareholders: Grabar Law Investigates Claims on Your Behalf PHILADELPHIA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company. globenewswire.com 2025-02-04 12:34:00 Czytaj oryginał (ang.)
Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on February 25, 2025 PRINCETON, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. globenewswire.com 2025-02-04 10:30:00 Czytaj oryginał (ang.)
IART vs. SONVY: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors? zacks.com 2025-01-22 14:46:40 Czytaj oryginał (ang.)
Is Integra LifeSciences (IART) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2025-01-22 12:41:01 Czytaj oryginał (ang.)
5 Price-to-Book Value Stocks With Great Prospects The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, IART, GBX, TRTX and ENS are some such stocks. zacks.com 2025-01-21 18:01:08 Czytaj oryginał (ang.)
4 Intriguing Value Stocks to Add to Your Portfolio Now Value investing is essentially about selecting cheap but fundamentally sound stocks. TSN, GM, IART and ENS boast low P/CF ratios. zacks.com 2025-01-20 13:15:18 Czytaj oryginał (ang.)
Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs) New global medical education platform offers digital tools to keep HCPs at the forefront of medical knowledge New global medical education platform offers digital tools to keep HCPs at the forefront of medical knowledge globenewswire.com 2025-01-14 10:30:00 Czytaj oryginał (ang.)
IART or PEN: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now? zacks.com 2025-01-06 14:46:17 Czytaj oryginał (ang.)
Invest in These 4 Value Stocks for Promising 2025 Returns Value investing is essentially about selecting stocks that are cheap but fundamentally sound. TSN, GM, MGNI & IART boast a low P/CF ratio. zacks.com 2025-01-06 13:35:41 Czytaj oryginał (ang.)
Is Integra LifeSciences (IART) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2025-01-06 12:46:17 Czytaj oryginał (ang.)
Here's Why You Should Hold IART Stock in Your Portfolio Now Integra's growth within its Tissue Technologies business segment bolsters investors' confidence in the stock. zacks.com 2024-12-31 09:56:17 Czytaj oryginał (ang.)
Reasons to Retain IART Stock in Your Portfolio for Now Integra's strong growth in the CSS business segment bolsters investors' confidence in the stock. Meanwhile, the weak liquidity position adds to the worry. zacks.com 2024-11-25 10:51:10 Czytaj oryginał (ang.)
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant According to a health economic evaluation, Integra's DuraSeal Dural Sealant is revealed to reduce healthcare costs. zacks.com 2024-11-14 11:25:31 Czytaj oryginał (ang.)
Integra's DuraSeal® Dural Sealant Saves Healthcare Costs According to an Economic Evaluation Published in the Journal of Comparative Effectiveness Research The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of fibrin glue The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of fibrin glue globenewswire.com 2024-11-13 18:10:00 Czytaj oryginał (ang.)
Integra Q3 Earnings, Revenues Beat, Stock Up Despite Margin Pressure IART is optimistic about the fact that the shipping holds have largely been resolved within the third quarter. zacks.com 2024-11-05 14:26:11 Czytaj oryginał (ang.)
Integra LifeSciences Holdings Corporation (IART) Q3 2024 Earnings Call Transcript Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q3 2024 Earnings Call Transcript November 4, 2024 8:30 AM ET Company Participants Chris Ward - IR Stuart Essig - Executive Chairman Jan De Witte - President and CEO Lea Knight - CFO Conference Call Participants Steven Lichtman - Oppenheimer Vik Chopra - Wells Fargo Ryan Zimmerman - BTIG Kristen Stewart - C.L. King Robbie Marcus - JPMorgan Matt Taylor - Jefferies Richard Newitter - Truist Securities Craig Bijou - Bank of America Securities Joanne Wuensch - Citi Chris Ward Good morning and thank you for joining the Integra LifeSciences Third Quarter 2024 Earnings Conference Call. seekingalpha.com 2024-11-04 19:27:16 Czytaj oryginał (ang.)
Integra (IART) Reports Q3 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com 2024-11-04 12:31:08 Czytaj oryginał (ang.)
Integra LifeSciences (IART) Beats Q3 Earnings and Revenue Estimates Integra LifeSciences (IART) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.76 per share a year ago. zacks.com 2024-11-04 10:16:07 Czytaj oryginał (ang.)
Integra LifeSciences Reports Third Quarter 2024 Financial Results PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2024. globenewswire.com 2024-11-04 08:03:00 Czytaj oryginał (ang.)
Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer A proven healthcare executive with deep global expertise and a distinguished record in business strategy and execution, portfolio transformation, value-creating innovation, commercial excellence, and leadership development A proven healthcare executive with deep global expertise and a distinguished record in business strategy and execution, portfolio transformation, value-creating innovation, commercial excellence, and leadership development globenewswire.com 2024-11-04 08:00:00 Czytaj oryginał (ang.)
Integra LifeSciences to Host Third Quarter 2024 Financial Results Conference Call on November 4, 2024 PRINCETON, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2024 financial results on Monday, November 4, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. globenewswire.com 2024-10-14 12:00:00 Czytaj oryginał (ang.)
Here's Why You Should Hold IART Stock in Your Portfolio Now Integra's strong growth in the Tissue Technologies and CSS business segment bolsters investors' confidence in the stock. zacks.com 2024-10-04 14:05:26 Czytaj oryginał (ang.)
Integra LifeSciences to Present at the 22nd Annual Morgan Stanley Healthcare Conference PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will present at the Morgan Stanley Healthcare conference on September 6, 2024 at 10:45am ET. globenewswire.com 2024-09-04 20:01:00 Czytaj oryginał (ang.)
Integra LifeSciences to Present at the 2024 Wells Fargo Healthcare Conference PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer, will present at the Wells Fargo Healthcare conference on September 4, 2024 at 1:30pm ET. globenewswire.com 2024-09-04 14:32:00 Czytaj oryginał (ang.)
Integra LifeSciences Continues to Make Progress on Its ESG Strategy The company published its third ESG report, underscoring its values and commitment to restoring lives The company published its third ESG report, underscoring its values and commitment to restoring lives globenewswire.com 2024-08-21 20:15:00 Czytaj oryginał (ang.)
Integra's (IART) Q2 Earnings and Revenues Top, Margins Down Integra's (IART) second-quarter 2024 results reflect strong demand for its diverse portfolio of leading brands and the continued successful market adoption of CereLink. zacks.com 2024-07-30 17:51:08 Czytaj oryginał (ang.)
Integra LifeSciences Analysts Cut Their Forecasts After Q2 Results Integra LifeSciences IART reported upbeat second-quarter earnings and lowered its FY24 guidance below estimates on Monday. benzinga.com 2024-07-30 15:36:15 Czytaj oryginał (ang.)
Why Integra Lifesciences Stock Is Sinking Today Integra Lifesciences topped analysts' Q2 revenue and earnings estimates. However, the company reduced its full-year guidance. fool.com 2024-07-29 16:23:00 Czytaj oryginał (ang.)
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com 2024-07-29 14:31:40 Czytaj oryginał (ang.)
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Monday. benzinga.com 2024-07-29 12:24:00 Czytaj oryginał (ang.)